-
1.发明申请Method and kit for the diagnosis or treatment control of intestinal carcinoma 审中-公开肠癌诊断或治疗控制的方法和试剂盒公开(公告)号：US20060246430A1
公开(公告)日：2006-11-02
申请号：US10488728
申请日：2002-09-06
CPC分类号： C07K16/30 , G01N33/54326 , G01N33/56966 , G01N33/57492
摘要： The invention relates to a diagnosis kit and to a method for the diagnosis or treatment control of intestinal carcinoma in a human being. According to the invention, the presence or absence of at least two different messenger-RNAs coding for several of the tumor marker proteins CK20, EGF-R, CEA, GA733.2, PDGF-β and/or stanniocalcin is detected in a human blood sample. The presence of intestinal tumor cells in the blood sample is then deduced therefrom, as is possible metastatic spread.
摘要翻译： 本发明涉及诊断试剂盒和用于人类肠癌诊断或治疗控制的方法。 根据本发明，在人血液中检测到编码几种肿瘤标志物蛋白CK20，EGF-R，CEA，GA733.2，PDGF-β和/或铁蓝蛋白的至少两种不同信使RNA的存在或不存在 样品。 然后从血液样本中推断出肠肿瘤细胞的存在，如可能的转移扩散。
-
2.发明授权Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells 有权用于选择和/或定性和/或定量检测细胞的方法和诊断试剂盒公开(公告)号：US07507528B2
公开(公告)日：2009-03-24
申请号：US10488729
申请日：2002-05-17
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： G01N33/57492 , C07K16/30 , G01N33/54326 , G01N33/56966
摘要： This invention relates to a method for selecting and/or for qualitative and/or quantitative detection of predetermined biological cells from or in a sample containing biological cells, the sample being mixed with a predetermined combination of at least two antibodies and/or antibody derivatives, which bind preferentially with their binding sites to different epitopes of the cells to be selected or detected, and/or with at least one biospecific antibody and/or antibody derivative, which binds preferentially with its two binding sites to different epitopes of the cells to be selected or detected, which are separated from the sample with cells marked with at least one of the antibodies and/or antibody derivatives, and the separated cells being tested with a predetermined combination of at least two molecular-biological detection reagents, the at least two detection reagents reacting preferentially with at least one component of the cells to be selected or detected.
摘要翻译： 本发明涉及用于从含有生物细胞的样品中或在含有生物细胞的样品中选择和/或定性和/或定量检测预定生物细胞的方法，所述样品与至少两种抗体和/或抗体衍生物的预定组合混合， 其优先与其结合位点结合至待选择或检测的细胞的不同表位，和/或与至少一种生物特异性抗体和/或抗体衍生物结合，所述生物特异性抗体和/或抗体衍生物优先与其两个结合位点结合至细胞的不同表位， 选择或检测，其与标记有至少一种抗体和/或抗体衍生物的细胞与样品分离，并且分离的细胞用至少两种分子生物检测试剂的预定组合进行测试，所述至少两种 检测试剂优选与待选择或检测的细胞的至少一种成分反应。
-
3.发明申请Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells 有权用于选择和/或定性和/或定量检测细胞的方法和诊断试剂盒公开(公告)号：US20050042685A1
公开(公告)日：2005-02-24
申请号：US10488729
申请日：2002-05-17
IPC分类号： C07K16/30 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N21/78 , G01N33/48 , G01N33/543 , G01N33/569 , G01N33/574 , G01N33/53 , G01N33/567
CPC分类号： G01N33/57492 , C07K16/30 , G01N33/54326 , G01N33/56966
摘要： This invention relates to a method for selecting and/or for qualitative and/or quantitative detection of predetermined biological cells from or in a sample containing biological cells, the sample being mixed with a predetermined combination of at least two antibodies and/or antibody derivatives, which bind preferentially with their binding sites to different epitopes of the cells to be selected or detected, and/or with at least one biospecific antibody and/or antibody derivative, which binds preferentially with its two binding sites to different epitopes of the cells to be selected or detected, which are separated from the sample with cells marked with at least one of the antibodies and/or antibody derivatives, and the separated cells being tested with a predetermined combination of at least two molecular-biological detection reagents, the at least two detection reagents reacting preferentially with at least one component of the cells to be selected or detected.
摘要翻译： 本发明涉及用于从含有生物细胞的样品中或在含有生物细胞的样品中选择和/或定性和/或定量检测预定生物细胞的方法，所述样品与至少两种抗体和/或抗体衍生物的预定组合混合， 其优先与其结合位点结合至待选择或检测的细胞的不同表位，和/或与至少一种生物特异性抗体和/或抗体衍生物结合，所述生物特异性抗体和/或抗体衍生物优先与其两个结合位点结合至细胞的不同表位， 选择或检测，其与标记有至少一种抗体和/或抗体衍生物的细胞与样品分离，并且分离的细胞用至少两种分子生物检测试剂的预定组合进行测试，所述至少两种 检测试剂优选与待选择或检测的细胞的至少一种成分反应。
-
4.发明申请Method and kit for diagnosing or controlling the treatment of breast cancer 审中-公开用于诊断或控制乳腺癌治疗的方法和试剂盒公开(公告)号：US20050014208A1
公开(公告)日：2005-01-20
申请号：US10488828
申请日：2002-09-06
IPC分类号： C07K16/30 , G01N33/543 , G01N33/569 , G01N33/574 , C12M1/34
CPC分类号： G01N33/54326 , C07K16/30 , G01N33/56966 , G01N33/57492
摘要： The present invention pertains to a procedure and a kit for the diagnosis or monitoring of breast cancer in humans. This procedure is based on the feature that one recognizes the presence or absence in a human blood sample of at least two different mRNAs that code for various members of the tumor marker proteins EGF-R, CEA, stanniocalcin, CK20, MAGE-3, GA733.2, MUC1, Her-2/neu, claudin-7, and/or PDGF-β, and a conclusion is drawn from this in regard to the presence of mammary carcinoma cells in the blood sample, and thus in regard to possible metastasis.
摘要翻译： 本发明涉及用于诊断或监测人类乳腺癌的方法和试剂盒。 该过程基于以下特征：人们认识到编码肿瘤标志物蛋白EGF-R，CEA，猕猴桃，CK20，MAGE-3，GA733的各种成员的至少两种不同mRNA的人血液样品中的存在或不存在 .2，MUC1，Her-2 / neu，claudin-7和/或PDGF-β，从血液样品中乳腺癌细胞的存在以及关于可能转移的结论 。
-
5.发明申请Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer 审中-公开诊断试剂盒，dna芯片，诊断或监督睾丸癌治疗方法公开(公告)号：US20050118591A1
公开(公告)日：2005-06-02
申请号：US10496410
申请日：2001-11-22
IPC分类号： C07K16/30 , G01N33/543 , G01N33/569 , G01N33/574 , C12Q1/68 , C12M1/34
CPC分类号： C07K16/30 , G01N33/54326 , G01N33/56966 , G01N33/57492
摘要： The invention relates to a diagnosis kit, a DNA chip, and to methods for diagnosing or supervising the treatment of testicular cancer, which are of greatest importance, in particular, within the scope of cancer prevention and post-treatment. The invention is essentially characterized in that the mRNA of testicular tumor markers is detected in a blood sample, whereby the tumor markers depict a tumor-associated gene expression. To this end, particularly β-hCG, AFP, PLAP or GCAP come into question. The detection of the mRNA is carried out by reverse transcription in cDNA and by subsequently amplifying selected segments of the cDNA by means of polymerase chain reaction.
摘要翻译： 本发明涉及诊断试剂盒，DNA芯片，以及用于诊断或监督睾丸癌治疗的方法，其特别是在癌症预防和后处理的范围内是最重要的。 本发明的基本特征在于，在血液样品中检测到睾丸肿瘤标志物的mRNA，由此肿瘤标志物描绘肿瘤相关基因表达。 为此，特别是beta-hCG，AFP，PLAP或GCAP受到质疑。 mRNA的检测通过cDNA中的逆转录和随后通过聚合酶链反应扩增cDNA的选定区段来进行。
-
-
-
-
搜索结果
5 条记录 (耗时 0.02 秒)
